Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

No Link Between Abortions and Breast Cancer Risk

April 1, 2003
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 12 No 4
Volume 12
Issue 4

BETHESDA, Maryland-Well-established epidemiological evidence shows that neither an induced nor a recognized spontaneous abortion increases a woman’s risk of breast cancer, a workshop convened by the National Cancer Institute (NCI) concluded after an extensive review of the available scientific data. However, important gaps exist in the understanding of how events prior to and during pregnancy may affect a woman’s risk of malignant breast tumors, and those gaps need to be filled, the workshop’s report added (see Table).

BETHESDA, Maryland—Well-established epidemiological evidence shows that neither an induced nor a recognized spontaneous abortion increases a woman’s risk of breast cancer, a workshop convened by the National Cancer Institute (NCI) concluded after an extensive review of the available scientific data. However, important gaps exist in the understanding of how events prior to and during pregnancy may affect a woman’s risk of malignant breast tumors, and those gaps need to be filled, the workshop’s report added (see Table).

The "Early Reproductive Events and Breast Cancer Workshop" attracted some 120 scientists to assess the state of the evidence regarding breast cancer risk factors associated with pregnancy. At one point, the public meeting was closed so that researchers could present new and unpublished findings.

Epidemiologist Leslie Bernstein, PhD, of the University of Southern California’s Keck School of Medicine, presented the workshop’s findings and recommendations to a joint meeting of NCI’s Board of Scientific Counselors and Board of Scientific Advisors. After hearing her report, the two boards voted unanimously to accept the workshop report.

Federal law requires that an NCI advisory board accept such a report before it can be forwarded to the institute’s director for consideration and action.

The issue of whether induced abortions increase breast cancer risk—which in part stimulated NCI director Andrew C. von Eschenbach, MD, to convene the workshop—drew considerable public attention to the meeting. A few studies have indicated a possible link. However, the workshop rated the evidence "well established" that an abortion, whether induced or spontaneous and recognized by the woman, does not increase the risk of breast cancer. The researchers could not address the issue of all spontaneous abortions because "a large portion of spontaneous abortions are not recognized by women, and it is difficult to record those," Dr. Bernstein said.

Other Epidemiological Findings

Six other epidemiological findings received well-established ratings: (1) Early age at first term birth is related to a lifetime decrease in breast cancer risk; (2) increasing parity is associated with a long-term risk reduction, even when controlling for age at first birth; (3) the additional long-term protective effect of young age at subsequent term pregnancies is not as strong as for the first term pregnancy; (4) a nulliparous woman has approximately the same breast cancer risk as a woman with a first term birth around age 30; (5) breast cancer risk is transiently increased after a term pregnancy; and (6) long-duration lactation provides a small additional risk reduction after consideration of age at, and number of, term pregnancies.

Workshop participants did not find the clinical evidence regarding pregnancy-associated risk factors for breast cancer to be as strong as the epidemiologic literature. They concluded that the "weight of the evidence" favors the idea that a long-lasting decrease in mammographic density follows pregnancy. The workshop found other clinical evidence to be in the category of "suggested from human population studies but speculative." These were that changes in breast histology can be correlated with risk in premenopausal women, and that prolactin, estradiol, and IGF-1 are decreased after pregnancy,

Future Research

Workshop participants recommended that NCI pursue 11 issues in future research aimed at answering questions about pregnancy and breast cancer. These included developing additional animal and treatment models, examining the molecular mechanisms of hormone-induced protection, pursuing descriptive studies about human breast development in order to formulate new hypotheses, pursuing international studies to develop hypotheses for observed international differences in breast cancer risk, developing surrogate markers to identify the risk of breast cancer following pregnancy, and translating knowledge about protective effects of pregnancy into intervention trials with human populations.

The summary report can be found at http://www.nci.nih.gov/cancerinfo/ere-workshop-report.

Articles in this issue

Accuracy of Ductal Lavage Tested
Preventing Anemia Maintains QOL During Adjuvant Chemo
Blocking EGFR Pathway May Boost Tamoxifen Response
Omitting Post-lumpectomy RT Lowers Survival in Elderly
Ovarian Cancer Survival Significantly Improved: SEER Data
No Link Between Abortions and Breast Cancer Risk
Imatinib Reduces Leukemia Load, Prolongs CML Remissions
First Studies of Whole-Body Screening CT Mixed
Zometa Stops Bone Loss During Endocrine Rx for Breast Cancer
Swedish Study Finds Increased Risk of Breast Cancer With Progestin-Containing HRT
IBCSG Trials of Chemoendocrine Rx
Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content
Advertisement

HER2 Amplicon mRNA Signature May Determine Positive Outcomes With T-DXd in mBC

HER2 Amplicon mRNA Signature May Determine Positive Outcomes With T-DXd in mBC

Ariana Pelosci
June 2nd 2025
Article

“Higher pretreatment HER2 amplicon mRNA signature and HER2 protein expression predicted improved outcomes with T-DXd for [metastatic breast cancer],” Paolo Tarantino, MD, PhD, said.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Gina Mauro
June 1st 2025
Article

Data from the phase 3 NATALEE trial confirms ribociclib plus NSAI consistently improves survival outcomes in stage II/III HR+/HER2– early breast cancer patients, regardless of age or menopausal status.


Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


Camizestrant and continued CDK4/6 inhibition delayed time to QOL deterioration vs SOC therapy in ER+/HER2– advanced breast cancer.

Camizestrant Enhances PFS vs AI Inhibitor in ER+/HER2– Breast Cancer

Caroline Seymour
June 1st 2025
Article

Camizestrant and continued CDK4/6 inhibition delayed time to QOL deterioration vs SOC therapy in ER+/HER2– advanced breast cancer.


Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer

Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer

Kyle Doherty
June 1st 2025
Article

Patients who received ipatasertib/fulvestrant in the intention-to-treat population achieved a median PFS of 5.32 months compared with 1.94 months in the placebo arm.

Related Content
Advertisement

HER2 Amplicon mRNA Signature May Determine Positive Outcomes With T-DXd in mBC

HER2 Amplicon mRNA Signature May Determine Positive Outcomes With T-DXd in mBC

Ariana Pelosci
June 2nd 2025
Article

“Higher pretreatment HER2 amplicon mRNA signature and HER2 protein expression predicted improved outcomes with T-DXd for [metastatic breast cancer],” Paolo Tarantino, MD, PhD, said.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

Gina Mauro
June 1st 2025
Article

Data from the phase 3 NATALEE trial confirms ribociclib plus NSAI consistently improves survival outcomes in stage II/III HR+/HER2– early breast cancer patients, regardless of age or menopausal status.


Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


Camizestrant and continued CDK4/6 inhibition delayed time to QOL deterioration vs SOC therapy in ER+/HER2– advanced breast cancer.

Camizestrant Enhances PFS vs AI Inhibitor in ER+/HER2– Breast Cancer

Caroline Seymour
June 1st 2025
Article

Camizestrant and continued CDK4/6 inhibition delayed time to QOL deterioration vs SOC therapy in ER+/HER2– advanced breast cancer.


Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer

Ipatasertib/Fulvestrant Combo Prolongs PFS in ER+/HER2– Metastatic Breast Cancer

Kyle Doherty
June 1st 2025
Article

Patients who received ipatasertib/fulvestrant in the intention-to-treat population achieved a median PFS of 5.32 months compared with 1.94 months in the placebo arm.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.